Acute retinal necrosis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Bot: Removing from Primary care) |
||
(One intermediate revision by one other user not shown) | |||
Line 12: | Line 12: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Ophthalmology]] | [[Category:Ophthalmology]] | ||
[[Category:Emergency medicine]] | |||
[[Category:Disease]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Infectious disease]] |
Latest revision as of 20:16, 29 July 2020
Acute retinal necrosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Acute retinal necrosis future or investigational therapies On the Web |
American Roentgen Ray Society Images of Acute retinal necrosis future or investigational therapies |
FDA on Acute retinal necrosis future or investigational therapies |
CDC on Acute retinal necrosis future or investigational therapies |
Acute retinal necrosis future or investigational therapies in the news |
Blogs on Acute retinal necrosis future or investigational therapies |
Risk calculators and risk factors for Acute retinal necrosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Luke Rusowicz-Orazem, B.S.